R
Rongsheng Zheng
Researcher at Bengbu Medical College
Publications - 12
Citations - 757
Rongsheng Zheng is an academic researcher from Bengbu Medical College. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 4, co-authored 8 publications receiving 573 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li,Shukui Qin,Jianming Xu,Jianping Xiong,Changping Wu,Yuxian Bai,Wei Liu,Jiandong Tong,Yunpeng Liu,Rui-Hua Xu,Zhehai Wang,Qiong Wang,Xuenong Ouyang,Yan Yang,Yi Ba,Jun Liang,Xiaoyan Lin,Deyun Luo,Rongsheng Zheng,Xin Wang,Guoping Sun,Liwei Wang,Leizhen Zheng,Hong Guo,Jingbo Wu,Nong Xu,Jianwei Yang,Hong-gang Zhang,Ying Cheng,Ningju Wang,Lei Chen,Zhining Fan,Piaoyang Sun,Hao Yu +33 more
TL;DR: These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Journal ArticleDOI
A prospective study to evaluate the efficacy and safety of oral acetyl‑L‑carnitine for the treatment of chemotherapy‑induced peripheral neuropathy
Yuanjue Sun,Yongqian Shu,Baorui Liu,Ping Liu,Changping Wu,Rongsheng Zheng,Xiaohua Zhang,Zhixiang Zhuang,Yongchuan Deng,Leizhen Zheng,Qing Xu,Bin Jiang,Xuenong Ouyang,Jianfei Gao,Nong Xu,Xiaoyi Li,Su Jiang,Chaofan Liang,Yang Yao +18 more
TL;DR: It is demonstrated that in Chinese patients with cancer, oral administration of ALC is effective at ameliorating peripheral sensory neuropathy induced by chemotherapy, as well as reducing of cancer-associated fatigue and improving physical conditions.
Journal ArticleDOI
Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.
Yuankai Shi,Yanqiu Zhao,Sheng Yang,Jianying Zhou,Liangming Zhang,Gongyan Chen,Jian Fang,Bo Zhu,Xing-Ya Li,Yongqian Shu,Jian Hua Shi,Rongsheng Zheng,Donglin Wang,Hui-Qing Yu,Jian'An Huang,Zhixiang Zhuang,Gang Wu,Longzhen Zhang,Zhongliang Guo,Michael Greco,X. Li,Yu Zhang +21 more
TL;DR: In this paper , the authors evaluated the safety, efficacy, and pharmacokinetics of rezivertinib for patients having advanced NSCLC with EGFR T790M mutation.
Journal ArticleDOI
A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN).
Yuanjue Sun,Baorui Liu,Ping Liu,Changping Wu,Rongsheng Zheng,Xiaohua Zhang,Zhixiang Zhuang,Yongchuan Deng,Leizhen Zheng,Qing Xu,Bin Jiang,Xuenong Ouyang,Jianfei Gao,Su Jiang,Wei Zheng,Benjamin Xiaoyi Li,Yongqian Shu,Yang Yao +17 more
TL;DR: This study evaluated the efficacy and safety of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablet (oral administration) in the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Journal ArticleDOI
Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1
Fengyi Feng,Qing Li,Changquan Ling,Yang Zhang,Feng-Zhan Qin,Huaqing Wang,Wen-Xia Huang,Shun-Chang Jiao,Qiang Chen,Mingzhong Li,Yun-zhong Zhu,Mei-zhen Zhou,Jun Ren,Yetao Gao,Jingpo Zhao,Rongsheng Zheng,Wen-hua Zhao,Zhiqiang Meng,Fang Li,Qi-zhong Zhang,Dongli Zhao,Liyan Xu,Yongqiang Zhang,Yanjun Zhang,Zhenjiu Wang,Shuanqi Liu,Ming C. Liau +26 more
TL;DR: Modulation of abnormal methylation enzymes by CDA-2 is definitely helpful to supplement chemotherapy and significantly increased the therapeutic efficacy and reduced the toxic manifestation of cytotoxic chemotherapy on breast cancer and NSCLC.